White Paper

Pretreated Patient-derived Xenograft Models: A Key Tool for Developing Innovative Anticancer Therapies

There is an immediate unmet need for preclinical models that can help researchers better understand the mechanisms of drug resistance, especially in the context of modern clinical treatments, so that more effective drugs can be developed.

Next generation pretreated PDX models have promising applications to meet this unmet need.

This white paper discusses how PDX models are ideal for preclinical testing of new anticancer agents while emphasizing that these models must evolve to reflect today’s current patient populations.

Advantages, current limitations, and new developments to overcome limitations in PDX model systems are presented.

The white paper includes three case studies highlighting the establishment and validation of several pretreated PDX models (colorectal cancer, prostate cancer, and breast cancer).

Download this White Paper to Discover:

• Advantages of PDX models
• Why PDX models can more effectively bridge the gap between lab and clinic
• The importance of next generation PDX models that continually evolve to reflect today’s treatments and patient populations
• Case studies and expert insights in the utilization of next generation PDX models

Download the White Paper Now!